Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up
Journals
Journal of the National Compre...
Journal of the National Comprehensive Cancer Network : JNCCN
#1
JOURNAL ARTICLE
Chengwei Peng, Saad Saffo, Paul E Oberstein, Michael Shusterman, Charlene Thomas, Daniel J Becker, Jordan D Berlin, Lawrence P Leichman, Ben Boursi, Anil B Nagar, Shun Yu
BACKGROUND: 5-Fluorouracil (5-FU) is a major component of gastrointestinal cancer treatments. In multidrug regimens such as FOLFOX, FOLFIRI, and FOLFIRINOX, 5-FU is commonly administered as a bolus followed by an infusion. However, the pharmacologic rationale for incorporating the 5-FU bolus in these regimens is unclear, and there are other effective regimens for gastrointestinal cancers that do not include the bolus. The purpose of this study was to determine whether omission of the 5-FU bolus was associated with a difference in survival and toxicity...
September 5, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#2
JOURNAL ARTICLE
Saranya Chumsri, Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Katherine L Pogue-Geile, Priya Rasgoti, Soonmyung Paik, Edith A Perez, E Aubrey Thompson
BACKGROUND: The Clinical Treatment Score post-5 years (CTS5) is a risk stratification tool used to determine the risk of late recurrence in hormone receptor-positive (HR+), HER2-negative breast cancer (BC). Limited data exist on its use in HR+, HER2-positive (HER2+) BC. PATIENTS AND METHODS: CTS5 was evaluated in HR+, HER2+ BC in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) and NSABP B-31 (NRG) trials. RESULTS: A total of 1,862 patients with HR+, HER2+ BC without recurrence 5 years after enrollment were included...
August 27, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#3
JOURNAL ARTICLE
Rachel T Kurtzman, Lisa Mikesell, Benjamin F Crabtree
BACKGROUND: Individuals with a history of cancer increasingly seek health information from online resources, including NCI-designated Cancer Center websites. Centers receive NCI designation because they provide excellent care and engage in cutting-edge research. However, the information presented on these webpages and their accessibility is unknown. An evaluation of the survivorship-focused webpages from NCI-designated Cancer Centers is needed to assess survivorship information and accessibility of these webpages...
August 16, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#4
JOURNAL ARTICLE
Keita Miura, Takehito Shukuya, Ray Greenstein, Ben Kaplan, Heather Wakelee, Kana Kurokawa, Kazuyuki Furuta, Shunsuke Kato, Junghee Suh, Smruthy Sivakumar, Ethan S Sokol, David P Carbone, Kazuhisa Takahashi
BACKGROUND: Some genomic alterations in non-small cell lung cancer (NSCLC) are known to differ according to race, sex, or age. These studies have been limited in sample size and thus they cannot detect the differences precisely and comprehensively. METHODS: Tissue-based comprehensive genomic profiling was performed on 75,362 patients with NSCLC from the United States during routine clinical care. Additionally, we examined data of a Japanese NSCLC cohort with 1,019 patients...
August 8, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#5
JOURNAL ARTICLE
Anna B Halpern, Jessica M Sugalski, Lindsey Bandini, Megan Othus, F Marc Stewart, Roland B Walter
BACKGROUND: Prolonged hospitalization following intensive (re)induction chemotherapy for acute myeloid leukemia (AML), while standard, is costly and resource intense, limits inpatient bed capacity, and negatively impacts quality of life. Early hospital discharge (EHD) following completion of chemotherapy has proven safe as an alternative at select institutions, but is not widely implemented. PATIENTS AND METHODS: From February 2023 through May 2023, the NCCN Best Practices Committee conducted a survey evaluating AML hospitalization patterns, care models, and barriers to EHD at its 33 member institutions...
July 30, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#6
JOURNAL ARTICLE
Kristen K Curtis, Nathan J Fakult, Jennifer L Strunck, Sumaira Z Aasi, Christine S Ahn, Murad Alam, Anna A Bar, Ramona Behshad, Christopher K Bichakjian, Diana Bolotin, Susan L Boone, Jeremy S Bordeaux, Jerry D Brewer, David R Carr, John A Carucci, Jason R Castillo, Sean R Christensen, Melanie A Clark, Lindsey K Collins, Addison M Demer, Daniel B Eisen, Hao Feng, Bahar F Firoz, Roy C Grekin, Jason M Hirshburg, Todd E Holmes, Conway C Huang, Thomas A Jennings, Shang I Brian Jiang, Sailesh Konda, Justin J Leitenberger, Jesse M Lewin, Ian A Maher, Elise Ng, Ida F Orengo, Faramarz H Samie, Drew K Saylor, Victoria Rose Sharon, Teo Soleymani, Susan M Swetter, Jesalyn A Tate, Marta J Van Beek, Nahid Y Vidal, Alok Vij, Ashley Wysong, Yaohui Gloria Xu, Bryan T Carroll, Wesley Y Yu
BACKGROUND: Mohs micrographic surgery (MMS) is a promising treatment modality for melanoma in situ (MIS). However, variations in surgical technique limit the generalizability of existing data and may impede future study of MMS in clinical trials. METHODS: A modified Delphi method was selected to establish consensus on optimal MMS techniques for treating MIS in future clinical trials. The Delphi method was selected due to the limited current data, the wide range of techniques used in the field, and the intention to establish a standardized technique for future clinical trials...
July 30, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#7
JOURNAL ARTICLE
Niels A D Guchelaar, Bo J Noordman, Marion W Welten, Myron T van Santen, Micha J de Neijs, Stijn L W Koolen, Rob H A Verhoeven, Esther Oomen-de Hoop, Pieter C van der Sluis, Sjoerd M Lagarde, Hanneke W M van Laarhoven, Ignace H J T de Hingh, Geert-Jan Creemers, Bianca Mostert, Bas P L Wijnhoven, Ron H J Mathijssen
BACKGROUND: Palliative systemic treatment is currently standard of care for metastatic gastric cancer. However, patients with peritoneal metastases of gastric origin are often underrepresented in clinical studies due to unmeasurable radiologic disease. This study describes the systemic treatment strategies and outcomes in patients with peritoneal metastases in a nationwide real-world setting. METHODS: Patients with gastric adenocarcinoma and synchronous peritoneal metastases (with or without other metastases) diagnosed in the Netherlands between 2015 and 2020 were identified from the nationwide Netherlands Cancer Registry...
July 29, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#8
JOURNAL ARTICLE
Jerrald Lau, Lina Choe, Daphne Hui Juan Lee, Athena Ming-Gui Khoo, Wei-Ling Koh, Cherie Peh, Alyssa Ng, Tian-Zhi Lim, Bettina Lieske, Kuok-Chung Lee, Choon-Seng Chong, Choon-Sheong Seow, Christopher H L Keh, Jing-Yu Ng, Ker-Kan Tan
BACKGROUND: Colorectal cancer (CRC) is one of the few cancers for which screening has been associated with better survival and morbidity, but screening uptake has been underexplored in spouses of existing patients with CRC. The objective of this study was to evaluate whether a brief, structured behavioral intervention delivered to spouses of patients with CRC in a colorectal clinical setting could increase fecal immunochemical test (FIT) uptake within 3 months of the study period. METHODS: This study was designed as a block randomized, unblinded, parallel trial conducted in the colorectal outpatient clinics of 2 public tertiary hospitals in Singapore from December 2017 to February 2023...
July 29, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#9
JOURNAL ARTICLE
Zilin Zhuang, Ailifeire Yilihamu, Zhihua Li, Rong Lei, Xun Li, Mengjia Han, Wei Wei, Guangxin Li, Zhen Ma, Yulu Zhang, Hui Hu, Xiaoyun Xiao, Yan Nie
BACKGROUND: Malignant phyllodes tumors (MPTs) are rare breast tumors with high risks of local recurrence and distant metastasis. Surgical intervention is the primary treatment, but the effectiveness of adjuvant therapies is uncertain. This study was designed to analyze the prognostic risk factors associated with MPTs and evaluate the efficacy of postoperative adjuvant chemotherapy. PATIENTS AND METHODS: Patients who were first diagnosed with MPT without distant metastasis and received R0 resection surgery between 1999 and 2023 were included in the present study and stratified into 2 groups: chemotherapy and nonchemotherapy groups...
July 29, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#10
JOURNAL ARTICLE
Goldy C George, Clark Andersen, Xiaohui Tang, Elizabeth Rodriguez, Midhat Jafry, Maria C Swartz, Sairah Ahmed, Carlos H Barcenas, J Andrew Livingston, Michael E Roth, Michelle A T Hildebrandt
BACKGROUND: The overall landscape of health-related quality of life (HRQoL) has not been thoroughly investigated in adolescents and young adults (AYAs) with cancer. Data are also lacking on how well HRQoL at the time of cancer diagnosis can prognosticate long-term survival in AYA survivors. PATIENTS AND METHODS: We included 3,497 survivors of AYA cancer (age 15-39 years at diagnosis) who completed the Short-Form 12 Health Survey (SF-12) HRQoL questionnaire at diagnosis...
July 12, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#11
JOURNAL ARTICLE
Merel J M van Velzen, Marieke Pape, Mirjam A G Sprangers, Jessy Joy van Kleef, Bianca Mostert, Laurens V Beerepoot, Marije Slingerland, Elske C Gootjes, Ronald Hoekstra, Lonneke V van de Poll-Franse, Nadia Haj Mohammad, Hanneke W M van Laarhoven
BACKGROUND: Chemotherapy for various stages of gastroesophageal cancer (GEC) is often neurotoxic. Chemotherapy-induced peripheral neuropathy (CIPN) impairs health-related quality of life (HRQoL). This study investigates the incidence and severity of CIPN and its association with HRQoL in patients with GEC. PATIENTS AND METHODS: Patients who received chemoradiotherapy or chemotherapy for GEC were identified from the Netherlands Cancer Registry. Patient-reported data (measured using the EORTC QLQ-CIPN20 and EORTC QLQ-C30) were collected through the Prospective Observational Cohort Study of Esophageal-Gastric Cancer Patients (POCOP) at baseline and at 3, 6, 9, 12, 18, and 24 months after treatment initiation...
July 8, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#12
JOURNAL ARTICLE
Carly C Barron, Tyler Pittman, Wei Xu, Mary Madunic, Niki Agelastos, David Goldstein, James Brierley, Monika K Krzyzanowska
BACKGROUND: The impact of COVID-19 pandemic-related disruptions on cancer services is emerging. We evaluated the impact of the first 2 years of the pandemic on new patient consultations for all cancers at a comprehensive cancer center within a publicly funded health care system and assessed whether there was evidence of stage shift. METHODS: We performed a retrospective study using the Princess Margaret Cancer Registry. New consultations with medical, radiation, or surgical oncology were categorized by year and quarter...
June 25, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#13
JOURNAL ARTICLE
Claudia Rosso, Naomie Devico Marciano, Deepika Nathan, Wen-Pin Chen, Christine E McLaren, Kathryn E Osann, Pamela L Flodman, May T Cho, Fa-Chyi Lee, Farshid Dayyani, Jason A Zell, Jennifer B Valerin
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling (GC) and germline testing regardless of family history. We hypothesized that patients with PDAC were more likely to be referred for testing after this change to the guidelines, regardless of presumed predictive factors, and that compliance would be further improved following the implementation of a hereditary cancer clinic (HCC)...
June 18, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#14
REVIEW
Aliza Gardenswartz, Mitchell S Cairo
Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody-drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand...
June 18, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#15
JOURNAL ARTICLE
Mackenzi Pergolotti, Kelley C Wood, Tiffany Kendig, Kim Love, Stacye Mayo
BACKGROUND: Breast cancer survivors (BCSs) report persistent, diminished ability to work, and decreased health-related quality of life (HRQoL). Cancer rehabilitation interventions (physical therapy or occupational therapy [PT/OT]) aim to improve these outcomes, but little is known about their impact in the community. METHODS: This retrospective, pre-post, uncontrolled study examined cases of younger BCSs (age <65 years) who attended cancer-specialized PT/OT over a 2-year period...
June 13, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#16
JOURNAL ARTICLE
Daniel M Geynisman
No abstract text is available yet for this article.
September 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#17
JOURNAL ARTICLE
Michael B Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Tyler Buckner, Robert Diep, Kleber Yotsumoto Fertrin, Annemarie E Fogerty, Nicolas Gallastegui Crestani, Radhika Gangaraju, Cristhiam Rojas-Hernandez, Samuel Z Goldhaber, Ibrahim Ibrahim, Timothy Kubal, Andrew D Leavitt, Ming Lim, Janelle Mann, Simon Mantha, Colleen Morton, Alex Nester, Andrew O'Brien, Thomas L Ortel, Alexander Pine, Allyson Pishko, Mona Ranade, Amirali Salmasi, Jordan Schaefer, Eliot Williams, Geoffrey Wool, Theodore Wun, Sarah Montgomery, Jamie Nguyen, Deborah Freedman-Cass, Bailee Sliker
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology...
September 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#18
JOURNAL ARTICLE
Scott Henderson, Mark Duggan, Chun Chao, Robert Cooper
BACKGROUND: Adolescent and young adult (AYA) patients with cancer have historically been understudied. Few studies have examined survival disparities associated with racial/ethnic and socioeconomic status (SES) and do not account for the influence of insurance status and access to care. We evaluated the association of SES and race/ethnicity with overall mortality for AYA patients who were members of an integrated health system with relatively equal access to care. METHODS: AYA patients diagnosed with the 15 most common cancer types during 2010 through 2018 at Kaiser Permanente Southern California were included...
September 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#19
REVIEW
Saurabh Zanwar, Prashant Kapoor
Waldenström macroglobulinemia (WM) is a B-cell lymphoma characterized by the presence of bone marrow lymphoplasmacytic infiltration and circulating monoclonal immunoglobulin M protein. The clinical presentation of WM is variable, ranging from gradually progressive cytopenias, organomegaly, fatigue, B symptoms, and peripheral neuropathy to the more emergent presentation with symptomatic hyperviscosity, cryoglobulinemia, hemolytic anemia-associated symptoms, acquired von Willebrand disease or acquired hemophilia-associated bleeding...
September 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#20
LETTER
Bridget Doherty, Silas Martin, Ágnes Benedict
No abstract text is available yet for this article.
September 2024: Journal of the National Comprehensive Cancer Network: JNCCN
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
